['psoriasis']
['sb414 6%', 'vehicle']

        Inclusion Criteria:

          -  Be male or female, 18-70 years old, and in good general health;

          -  Have a clinical diagnosis of stable chronic plaque psoriasis of mild to moderate
             severity based on the PSGA, involving 2-15% BSA (excluding the scalp/face), present
             for > 6 months;

          -  Must have at least 2 target plaques on trunk and/or extremities at least 5 cm2 with a
             TPSS > 5 and thickness sub-score > 2. Target plaques cannot be located on the groin,
             hands, feet, neck, face, elbows, knees, ankles or scalp;

          -  Be willing to not use any other systemic agents used to treat psoriasis or apply any
             other topical products (medicated or over-the-counter) to the treatment sites on the
             trunk and/or extremities during the study;

          -  Women of childbearing potential (WOCBP) must have a negative UPT prior to
             randomization and must agree to use an effective method of birth control during the
             study and for 30 days after their final study visit.

        Exclusion Criteria:

          -  Have inverse (i.e.: axillae, groin) or facial psoriasis only, erythrodermic psoriasis,
             guttate psoriasis, pustular psoriasis, drug-induced psoriasis, and /or psoriatic
             arthritis requiring treatment with disease modifying antirheumatic drugs (DMARDs);

          -  Concurrent or recent use of topical or systemic medications without a sufficient
             washout period;

          -  Are immunocompromised, including those who are known HIV positive or received
             immunosuppressive treatment within the past 6 months;

          -  Female subjects who are pregnant, nursing mothers, or planning to become pregnant
             during the study.
      